Upload
nia-tri-mulyani
View
218
Download
0
Embed Size (px)
Citation preview
8/13/2019 Medical Tribune December 2013
1/38
December 2013
www.mims.com
WHO shares new
strategy to end TB
Over-regulaon of
e-cigarees a potenal
threat to public health?
FORUM
Adult brain connues to
regenerate neurons
CONFERENCE
NEWS
IN PRACTICE
Treang hair loss
in women
BP lowering protects heart in early-
stage kidney disease
8/13/2019 Medical Tribune December 2013
2/38
2 December 2013
BP lowering protects heart in early-stage
kidney disease
Lianne Cowie
Lowering blood pressure is eective inpreventing cardiovascular events inpatients with mild or moderate kidney
disease, according to a large meta-analysis.Specically, blood pressure lowering
per se, not the eects of a particular drugclass... seems to be signicantly associatedwith lower cardiovascular risk in early-stage chronic kidney disease, possibly sug-gesting the importance of blood pressurelowering as a driver of cardiovascular riskreduction, said the authors of the report.
The Blood Pressure Lowering TreatmentTrialists Collaboration, a project funded bythe National Health and Medical ResearchCouncil of Australia, undertook a prospec-tive meta-analysis of 26 randomized trialsevaluating the ecacy of blood pressurelowering drugs against placebo, each oth-er, or specic blood pressure thresholds.All were required to have a minimum of1,000 patient-years of planned follow-up ineach randomized arm. The trials included152,290 individuals in total, 30,295 of whom
had a reduced estimated glomerular ltra-tion rate (eGFR)
8/13/2019 Medical Tribune December 2013
3/38
3 December 2013
Snoring in pregnancy a risk factor for
C-section, smaller babies
Rajesh Kumar
Pregnant women who snore three or
more nights a week have a higher risk
of poor delivery outcomes such as Ce-
sarean births and smaller babies, according to
the largest study of its kind.
Between March 2007 and December 2010,US researchers recruited 1,673 pregnant
women in their third trimester from prena-
tal clinics and followed them until delivery.
Women were screened for habitual snoring
as a known marker for sleep disordered
breathing. Outcome data were obtained
from medical records following delivery
and birth centiles were calculated. [Sleep
2013;36:1625-1632]A total of 35 percent women reported ha-
bitual snoring (26 percent with pregnancy-
onset snoring and 9 percent with chronic
snoring). Even aer accounting for other
risk factors, chronic snorers who snored be-
fore and during pregnancy were at the high-
est risks to have babies small for gestational
age (95% CI 1.02-2.66, p=0.041) and elective
C-sections (95% CI 1.22-4.18, p=0.008).More importantly, women who started
snoring only during pregnancy had a higher
risk of both elective and emergency C-sections
than women who did not snore. (95% CI 1.22-
2.30, p=0.001). An earlier study had linked
snoring during pregnancy with a high risk for
high blood pressure and preeclampsia.
[The ndings] suggest that we have a
window of opportunity to screen pregnant
women for breathing problems during sleep
that may put them at risk of poor delivery
outcomes, said lead author Dr. Louise
OBrien, associate professor at the Univer-
sity of Michigans Sleep Disorders Center in
the Department of Neurology and adjunct
associate professor in the Department of
Obstetrics & Gynecology at the U-M Medi-cal School in Ann Arbor, Michigan, US.
Screening pregnant women for symptoms
of sleep disordered breathing may provide
an early opportunity to identify women at
risk of poor delivery outcomes and treat
their obstructive sleep apnea using continu-
ous positive airway pressure (CPAP), the
researchers said.
Millions of healthcare dollars are spent on
operative deliveries, taking care of babies who
Pregnant women should be screened for breathing problems during theirsleep, according to new research.
8/13/2019 Medical Tribune December 2013
4/38
4 December 2013
are admied to the neonatal ICU and treating
secondary health problems that smaller babies
are at risk for when grown, OBrien added.
If we can identify risks during preg-
nancy that can be treated, we can reduce
the incidence of small babies, C-sections
and possibly neonatal ICU admissions that
not only improve long term health bene-
ts for newborns but also help keep costs
down.
READ JPOG ANYTIME, ANYWHERE.Downloadthe digital edition today at www.jpog.com
8/13/2019 Medical Tribune December 2013
5/38
5 December 2013 Forum
There has been much debate about the place of electronic nicotine delivery devices
(e-cigarees) in recent years, coincident with their ever increasing availability and popularity
across the world. Medicines agencies in the West have become increasingly concerned with
how to regulate these devices, which have the potential to act, and have been studied for their
eectiveness, as nicotine replacement therapies. Interestingly, while e-cigarees have their
supporters, not all are in favor of their regulation as medicines. Associate Professor Jean-
Franois Eer from the Faculty of Medicine, University of Geneva, Switzerland, provided thefollowing perspective, based on excerpts of his presentation at the recent E-Cigaree Summit
held in London, England.
Currently around the world, e-ciga-rees are mainly regulated as con-sumer products or tobacco products,
rather than medicines. However, impending
regulation amendments in Europe and the USare set to play a very important part in the fu-ture of these controversial products. Havingsaid this, there is no reason to expect that e-cigaree regulation will be the same in eachcountry. On the contrary, I think regulationswill dier between countries which take intolocal variations in factors such as stage of to-
bacco epidemic, history of tobacco regulation,political processes, weight of lobbies, and thestate of development of the e-cigaree mar-ket.
I believe that future e-cigaree regulationsin US and Europe will likely favor those whoare best at lobbying governments. And thiswill be detrimental to the smaller and mostinnovative players in this market the Chi-nese inventors and manufacturers. Big to-
bacco companies and big pharma will have
advantages they have so much expertiseworking within regulated environments.
They also have a lot of money, large and es-tablished customer bases, and existing shelfspace in shops. So they will be well placed tograb a large market share.
Currently in Europe, nicotine is regulatedin a way that I think is a disaster for publichealth. Throughout most of the continent, thecheapest and most deadly form of nicotine
in smoked tobacco is cheap and availableeverywhere, while smokeless nicotine is ei-
Over-regulation of e-cigarettes a potential
threat to public health?
8/13/2019 Medical Tribune December 2013
6/38
6 December 2013 Forum
ther banned or only available in medications(in patches or gums).
While nicotine replacement therapy (NRT)works, we know that dierences in long-term
quit rates between smokers given nicotinepatches or gums are only marginally beer (afew percentage points) compared with thosegiven placebo versions.
The success of e-cigarees is beginning tochallenge this approach and I think the reg-ulation of nicotine needs to be changed. Thequestion is how? Is it a good idea to regulatethe e-cigaree as a tobacco product and typi-
cally ban its use in public places, restrict ad-vertisements, sales, and use by minors, etc?E-cigarees are regulated as tobacco productsin some countries, even though they do notcontain tobacco. Nicotine is extracted from to-
bacco but does not contain tobacco. So its notvery logical.
There are several issues with placing strict-er controls on e-cigaree use. I think the ban-ning of e-cigaree vaping in public places,
for example, should require much strongerevidence that passive vaping is toxic or thatit encourages non-smokers to become vapersor smokers. Banning advertising, which helpsto inform consumers, is also a problematic is-sue.
One thing most people agree on howeveris that there should be restrictions for minors.However, even this is not straightforward
because minors who currently use nicotineor plan to use nicotine have no other choicebut to smoke in many countries. So providingthem an alternative way of geing nicotineis perhaps a controversial idea, but one thatshould not be rejected outright without fur-ther consideration.
I foresee several problems in regulating e-cigarees as medicines. Importantly, I thinkit will kill innovation. Take nicotine gum and
patches. They were invented in the 1970s and1980s and have almost not evolved since then.
Its not just the fault of the pharmaceuticalindustry but also the regulation frameworkwhich makes it so costly to improve a prod-uct. If such things as avors are banned for
example, then e-cigarees will become lessaractive. The other issue is what will hap-pen with all the unlicensed products? Theywill not miraculously disappear. Enforcementmay be very dicult, costly and ineective.Unlicensed products may end up on a blackmarket. Internet sales of unlicensed productswill continue for which there will be no man-datory quality control.
Other consequences of over-regulation willbe a trend towards fewer e-cigaree users,because of higher costs. Fewer smokers willtherefore quit and more will die. The entiree-cigaree market will become the domainof the tobacco industry because they are theonly ones with e-cigaree products almostready to be approved. I dont think this is adesirable outcome.
To conclude, I think e-cigarees are a ma-
jor innovation, a revolution in our eld, thathave the potential to save many lives. For reg-ulators, I think we should always keep in per-spective the huge number of deaths and dis-ease and misery caused by smoking tobacco.
The relative risk is relevant compared withcigarees because these products are used bysmokers. They dont need to be 100 percentsafe, only much safer than cigarees. Their
regulation as medicines or tobacco will bedisproportionate, and the prohibition of unli-censed products will not be feasible or desir-able.
The main danger for public health is theexcessive regulation of e-cigarees, not e-cig-arees themselves. Laws need to be changedto make room for safe recreational nicotineproducts, even if they are used compulsively,and this is one of the most important things
we have debated in public health in recent de-cades.
8/13/2019 Medical Tribune December 2013
7/38
7 December 2013 News
WHO shares new strategy to end TB
Dr. Yves Saint James Aquino
The End TB Strategy 2016-2035 aims
for a tuberculosis-free world by 2035
and is intended to immediately follow
the 2015 TB strategy and targets under the
Millennium Development Goals, shared Dr.
Tauhidul Islam, medical ocer with the Stop
TB Department of the World Health Organi-
zation-Western Pacic Region.Latest report from WHO has noted the es-
timated number of all forms of tuberculosis at
8.7 million and estimated number of deaths
due to TB at 1.4 million.
It means in a day, more than 3,000 patients
may die due to TB, and it means in one min-
ute, three people are dying, explained Islam.
And we know that TB is curable, so this situ-
ation is not acceptable.From data collected since 1990, the global
incidence rate peaked in 2000 and decreased
aer, with a fall of 2.2 percent per year from
2010 to 2011. Mortality rate is at 41-percent
decline since 1990, while prevalence rate is
at 36-percent decline. Both the incidence and
mortality rates are on track, but the preva-
lence rate is falling short of the development
goal.The End TB Strategy 2016-2035 is much
more ambitious having a target of 95-per-
cent reduction (compared with 2015 data) in
deaths and an incidence goal of less than 10
cases per 100,000 population, explained Is-
lam. There is also a mid-program goal of hav-
ing a 75-percent reduction in TB deaths and
less than 50 cases per 100,000 population by
2025.
According to Islam, despite the fact that 51
million patients are being cured and 20 mil-
lion lives have been saved since 1995, TB in-
cidence is still declining too slowly, with 1.4
million people still dying. He also stated that
response to multi-drug resistant TB (MDR-
TB) is slow and there are still gaps in nanc-
ing projects to ght the disease.Drug-resistant TB is a real challenge be-
cause the treatment duration is too long and
even aer treatment, the treatment outcome
is not really good enough, said Islam.
A quarter of the worldwide burden of
MDR-TB is seen in the Western Pacic Re-
gion, with more than 96 percent (79,000
cases) of that incidence shared by just three
countries that include China, Philippinesand Vietnam.
Islam explained that with the limitations
in funding, we must continue to prioritize
re-treatment cases and high-risk new cases
of MDR-TB. The government, apart from in-
creasing support for public health services,
should also engage the private sector in re-
porting cases, linking insurance coverage to
quality care and further optimizing public
service delivery.
The WHOs End TB Strategy 2016-2035 aims for a TB-free world by2035.
8/13/2019 Medical Tribune December 2013
8/38
8 December 2013 News
ASEAN countries come together to fight
NCDs
Dr. James Salisi
Members of the Association of South-east Asian Nations (ASEAN) Bru-nei Darussalam, Cambodia, In-
donesia, Lao Peoples Democratic Republic,Malaysia, Myanmar, Philippines, Singapore,Thailand and Vietnam met in Manila, Phil-ippines on October 14 to 16, 2013 for the FirstASEAN Regional Forum on Non-Communi-cable Diseases (NCDs) hosted by the Philip-pines Department of Health (DOH).
DOH Secretary Enrique Ona highlighted inhis keynote speech the importance of the fo-rum in light of the coming ASEAN integrationin 2015. It is with great pleasure to share withyou that the development cause and concern
has reached the highest political level withinthe ASEAN Community. The need to addressNCDs has been constantly in the priority ofASEAN Health Cooperation, Ona said.
He further emphasized that the shi in theglobal health burden to NCDs as the leadingcauses of mortality, morbidity and disabilityin recent years has prompted governmentsaround the world to drive public health inter-
ventions towards curbing the risk factors forNCDs such as smoking and obesity.The ASEAN forum serves as a venue to dis-
cuss the challenges for NCD prevention andcontrol, promotion of health lifestyle, and shar-ing of best public health practices in the region.It was an opportunity for ministries of healthin the region to showcase policies, programsand activities and to learn from these and eachother.
The forum has developed a Work Plan onNCDs for 2011 to 2015 to ensure the accessi-
bility of adequate and aordable health care,medical services, medicines and promotion ofhealthy lifestyle for the ASEAN population.
The Philippines was chosen as the leadcountry in holding the rst ASEAN Forum onNCDs following our model and experience
in staging the multi-sectoral Public HealthConvention on the Prevention and Control ofNCDs conducted every 2 years, Ona said.
It was an opportunity for the DOH to show-case its policies, programs and activities onNCDs, particularly the Sin Tax Law, Philip-pine Package of Essential NCD Interventionsand the Pilipinas Go4Health Healthy LifestyleMovement. During the forum, the Outstand-
ing Healthy Lifestyle Advocacy Awards werealso given out to the exemplary work of localgovernment units, non-government organiza-tions, business establishments and academicinstitutions who advocated NCD preventionmeasures.
The Bandar Seri Begawan Declaration onNon-communicable Diseases in ASEAN waspresented at the end of the 3-day forum. Gov-ernment ocials, public health experts and no-
table healthy lifestyle champions and expertsacross the region participated in the forum.
Delegates of the rst ASEAN Forum on NCDs (Photo credit:
Philippines DOH)
8/13/2019 Medical Tribune December 2013
9/38
9 December 2013 News
HRT needed for post-menopausal women
without frequent hot flashes?
Rajesh Kumar
Hormone replacement therapy (HRT)
may be of no use in improving the
quality of life of post-menopausal
women if they are not experiencing hot ash-
es, according to a study.
The researchers equally randomized 150recently menopausal women to HRT with
transdermal estradiol (1 mg/day), oral estra-
diol (2 mg/day) with or without medroxy-
progesterone acetate (5 mg/day), or placebo
for 6 months. Seventy-two women experi-
enced 7 moderate to severe hot ashes per
day, while the rest reported having 3 mild
hot ashes per day or none at all. [Menopause
2013; doi: 10.1097/gme.0000000000000120]In women with more hot ashes at base-
line, HRT use signicantly improved the
scores for sleep compared with placebo
(0.787 vs. 0.557, respectively, p=0.001), mem-
ory and concentration capacity (0.849 vs.
0.454, p
8/13/2019 Medical Tribune December 2013
10/38
10 December 2013 News
Higher dietary acid increases diabetes
risk in women
Rajesh Kumar
Higher dietary acid, regardless of the
individual foods making up that
diet, increases the risk of type 2 dia-
betes, according to a large study, the rst of
its kind, involving more than 60,000 women.
A diet rich in meat and other acidogenicfoods such as zzy drinks, condiments, junk
food, white bread and pasta can induce an
acid load that is not compensated for by fruit
and vegetables. This can cause chronic meta-
bolic acidosis and lead to metabolic compli-
cations. Increasing acidosis can reduce the
ability of insulin to bind at appropriate re-
ceptors in the body and reduce insulin sensi-
tivity, said the researchers. [Diabetologia2013;doi 10.1007/s00125-013-3100-0]
To test the hypothesis, they followed
66,485 women from the E3N* study for new
diabetes cases over 14 years. Their dietary
acid load was calculated from their potential
renal acid load (PRAL) and their net endog-
enous acid production (NEAP) scores, both
standard techniques for assessing dietary
acid consumption from nutrient intake.During follow-up, 1,372 new cases of type
2 diabetes occurred. In the overall population,
those in the top quartile for PRAL had a 56
percent increased risk of developing type 2
diabetes compared with the boom quartile.
Women of normal weight (body mass in-
dex [BMI] 25) had the highest increased risk
(96 percent for top quartile versus boom),
while overweight women (BMI 25) had
only a 28 percent increased risk (HR 1.28,
95% CI 1.00, 1.64). Statistically signicant
trends in risk across quartiles were observed
in both groups (p for trend
8/13/2019 Medical Tribune December 2013
11/38
11 December 2013 News
Breastfeeding prevents obesity in mother
and child
Dr. Maria Katrina Florcruz
The initiation of breastfeeding is an es-
sential part of intrapartum and new-
born care. Thereaer, the maintenance
of exclusive breastfeeding is highly encour-
aged because of the benets it can give to both
the mother and child, including obesity pre-vention.
According to Dr. Maria Asuncion Silves-
tre, neonatologist at the University of the
Philippines-Philippine General Hospital,
Manila, Philippines, breast milk contains
nutrients and minerals that are optimal for
the babys sleep, growth and development.
While appropriate solid food is introduced
at 6 months, breastfeeding should be contin-ued until 2 years and beyond.
Silvestre explains that there is beer ap-
petite regulation when an infant is exclu-
sively breastfed. This is due to the endo-
cannabinoid receptor system that is present
in the babys developing brain and in hu-
man milk. Due to this, there is regulation
of energy balance and food intake at four
functional levels within the brain and pe-riphery, namely the limbic system, hypo-
thalamus and hindbrain, intestinal system
and adipose tissue. [Exp Biol Med (May-
wood).2005;230(4):225-34]
Exclusive breastfeeding also prevents
forced feeding the baby, which is encoun-
tered in bole and formula feeding. At the
same time, the baby is not subjected to the
unchanging sweet and creamy taste of for-
mula, said the speaker.
Silvestre cited studies which showed that
breastfeeding for at least 2 months strongly
protects a baby from developing obesity later
in life. In addition, there is stronger protectionfrom obesity in babies who were exclusively
breastfed. [Pediatrics. 2005; 115:1367-1377]
In another study, it was found that there
is an inverse association between the dura-
tion of breastfeeding and the babys risk of
being overweight later in life.[Am J Epide-
miol.2005;162(5):397-403] Silvestre also cited
a cohort study done among school children
in Japan which showed that breastfeeding isassociated with a decreased risk of becom-
ing overweight and obese. [JAMA Pediatr.
2013;167(10):919-25]
Breastfeeding also protects mothers against
obesity, says Silvestre, as it requires an aver-
age of 500 extra calories per day. Breastfeed-
ing brings about short-term changes in in-
sulin and glucose. She further adds that for
every year that a mother breastfeeds, there isa corresponding decrease in risk in develop-
ing diabetes later in life. Breastfeeding helps a
mother return faster to her ideal body weight
and signicantly reduces hip circumference
as early as 1 month post-partum.
8/13/2019 Medical Tribune December 2013
12/38
12 December 2013 News
High-protein diet, meal replacements can
reduce rebound weight gain
Rajesh Kumar
Meal replacement and a high-proteindiet can help in maintaining weightloss by reducing rebound weight
gain, according to a meta-analysis of 20 ran-domized controlled trials (RCTs).
The body has several defense mechanismsagainst weight loss, such as increased hunger,lower energy metabolism and relapse to oldhabits, said researcher Dr. Erik Hemmings-son of the Karolinska Institutets Clinical Epi-demiology Unit and the Obesity Centre at Kar-olinska University Hospital in Solna, Sweden.
If the problem of rebound weight gaindidnt exist, obesity would be relatively easyto treat. There have been several possible
methods to facilitate long-term weight con-trol over the years, and now the database waslarge enough to make a systematic evaluationof existing studies.
Researchers combined the results of 20published RCTs involving 3,017 participantswho were either obese or overweight at thestart of the weight loss process. [Am J ClinNutr2014; doi: 10.3945/ajcn.113.070052]
The studies examined the eects of anti-obesity drugs (3 arms; n=658), meal replace-ments (4 arms; n=322), high-protein diets (6arms; n=865), other diets (3 arms; n=564), di-etary supplements (6 arms; n=261), and exer-cise (5 arms; n=347) on rebound weight gainaer an intensive weight loss on low-caloriediet of
8/13/2019 Medical Tribune December 2013
13/38
13 December 2013 News
Non-medical factors complicate weight-
loss surgeries
Dr. Yves Saint James Aquino
Apart from the medical and surgicalfactors, patients are aected by psy-chological, logistic and nancial rea-
sons that cause arition in bariatric surgery,said Dr. Jose Antonio Salud, chairman of the
Department of Surgery in The Medical City,Pasig, Philippines. Arition refers to patientsundergoing surgical operations for weightloss who fail to follow-up regularly and even-tually drop out, patients who fail to lose suf-cient weight or patients who regain weightover time.
Successful bariatric surgery is dened ashaving percent excess weight loss greaterthan or equal to 50 percent, according toReinholds criteria, a measure developed in1982.
Unfortunately, this denition is not evi-dence-based and it is arbitrary, said Salud.He claried that estimating ideal weightvaries and the criteria do not take into con-sideration the type of operation performed,which may involve lap-adjustable gastric
banding, lap sleeve gastrectomy or lap
Roux-en-Y gastric bypass.In reality, the goal of bariatric surgery
is to reduce the health risks associated withbeing obese and to improve health-relatedquality of life, Salud added.
Failure of patients to return aer sur-gery has been associated with post-oper-ative physical complication, poor weightloss, poor nutrition and poor resolution ofobesity-related comorbidities. Non-com-pliance to post-operative therapy may also
be caused by psychological, logistic and -
nancial diculties [Obes Surg.2012;22:1640-1647].
In the Philippines, close to 10 percent ofpatients live out of town and far from theclinic. Some patients claim to be busy or areafraid of further interventions, while othersfeel they can manage the problem withouthelp from their doctors. And since the sur-
gical procedure is typically excluded fromhealth insurance, patients could not aordsucceeding consultations.
Some of the technical reasons for thearition may involve band-related prob-lems, esophageal dysmotility or inadequatesleeve resection. Patients may also fail tolose substantial weight due to excessiveeating, abnormally low metabolic rate andhyper-ecient intestinal absorption [Surg
Obes Rel Dis.2005;1(6):573-579].Psychological predictors to inadequate
weight loss include personality disorders,history of binge eating, emotional eatersand history of depression. However, anxi-ety disorders, self-esteem issues, history ofsexual or alcohol abuse were not correlat-ed with inadequate weight loss [Obes Surg.2012;22(1):70-89].
Surgical correction aer primary bar-iatric operation is technically more di-cult, with higher rate of complications andmortality and lower success rate than therst procedure. Important non-medical as-pects of weight loss therapy such as proac-tive support and peri-operative counselingand education may minimize inadequateweight loss post-surgery. A multi-disciplin-ary care involving internists, psychologistsand other specialists may help prevent ari-tion in bariatric surgery, explained Salud.
8/13/2019 Medical Tribune December 2013
14/38
14 December 2013 News
Gestational weight gain may lead to obesity
Dr. James Salisi
Forty-ve percent of pregnant womenin the US are overweight or obese andalmost half begin their pregnancies as
either overweight or obese, according to astudy cited by Dr. Maria Jesusa Banal-Silao, afellow of the Philippine Society of Reproduc-tive Endocrinology and Infertility.
For women in the reproductive age, preg-nancy is a potential risk factor for the de-velopment of obesity. There is also a naturalincrease in body mass index (BMI) as thepregnancy progresses. Moreover, pregnan-cy can be a trigger for the development ofobesity due to excessive weight gain andlong term weight retention.
According to Banal-Silao, retainedweight after delivery may be harmful as the
adipose tissue tends to accumulate in thevisceral compartment. Evidence suggeststhat there are associations between exces-sive gestational weight gain and increased
birth weight and postpartum weight reten-tion.
The speaker further explained that ges-tational weight gain is a risk factor forshort-term post partum weight retention
and thus for becoming overweight in wom-en. An average of 1 to 2 kg of weight that isgained during pregnancy is retained at 6 to18 months postpartum. About 14 to 25 per-cent of women will have substantial weightretention of greater than 4.55 kg.
Gestational weight gain recommenda-tions by the Institute of Medicine (IOM) aimto optimize outcomes for the mother and in-fant. The maternal and infant outcomes for
obese and overweight women may not beadversely aected if they gain less than the
IOM recommendations.Banal-Silao added that gestational weight
gain (GWG) may also determine the long-term risk of being overweight in women. Ameta-analysis concluded that GWG in ac-
cordance with IOM recommendations is as-sociated with long-term eects on postpar-tum weight retention. [Am J Clin Nutr. 2011;94 (5): 1225-1231]
In order for postpartum women to dealwith excess GWG, Banal-Silao recom-mended regular monitoring of weight,promotion of appropriate pre-pregnancyweight gain and postpartum weight loss,
and encouragement of maintenance of anactive postpartum lifestyle and breast-feeding.
Banal-Silao said that breastfeeding thatis frequent and high-intensity is associ-ated with less postpartum weight reten-tion at all follow-up times. It may nothave an impact on short term weight loss
but women who breastfed their infants forat least 3 months had lower weight gain
at 8 years postpartum and lasted until15 years.
Gestational weight gain is a risk factor for short-term postpartum weightgain for women.
8/13/2019 Medical Tribune December 2013
15/38
15 December 2013 News
Lack of lactobacilli linked to vulvovaginal
atrophy
Angeline Woon
Menopausal women and those withvulvovaginal atrophy tend to haveless lactobacilli in their mid-vaginal
regions, say US researchers.The researchers, from Johns Hopkins
University and the University of Mary-land, characterized vaginal microbiota froma group of women between the ages of 35and 60. They found that the composition ofvaginal microbiota changes as women gothrough menopause.
Women with vulvovaginal atrophy, acommon cause of vaginal dryness and sex-ual pain, tended to have microbial composi-tions that were not dominated by lactobacilli.Compared to women with no vulvovaginalatrophy, the women with mild or moderatevulvovaginal atrophy had a 25-fold greaterodds of having a bacterial mix dominated
by microbes from the genus Streptococcusand Prevotella versus Lactobacillus crispatus(adjusted odds ratio, 25.89; 95% credible in-terval, 2.98-406.79).
Postmenopausal women tended to have
more microbes from the genus Streptococcusand Prevotella, as well. In comparison, wom-en whose vaginal microbiota were domi-nated by L. crispatusandL. inerstended to
be premenopausal. Perimenopausal womenwere more likely to be classied to have amix dominated by Streptococcus and Pre-votella, or L. gasseri, according to the studypublished in Menopause. [doi: 10.1097/
GME.0b013e3182a4690b]The study, led by lead author Dr. RebeccaBrotman (Ph.D.), assistant professor in the
department of epidemiology and publichealth at the University of Maryland Schoolof Medicine in Baltimore, Maryland, had87 participants. The women were classiedinto groups according to their menopausalstatus, premenopausal (n=30), perimeno-pausal (n=29) or postmenopausal (n=28) us-
ing the Stages of Reproductive Aging Work-shop guidelines. Out of the total, 19 womenhad signs of mild or moderate vulvovaginalatrophy.
The mid-vaginal region was sampled,and 16S ribosomal RNA gene analysis wasused to characterize the bacterial commu-nities, which were then clustered into sixmain community state types (CST). Four of
these CSTs were dominated byL. crispatus,L. gasseri, L. iners or L. jensenii.Two of theseCSTs had a low abundance of lactobacilli:one was dominated by the genus Streptococ-cusand Prevotella;and the other,Atopobium.Signicant associations could be made be-tween menopause stage and CST (P=0.004),and between vulvovaginal atrophy and CST(P=0.002).
The authors concluded that when levelsof lactobacilli are low, the vagina tends to bedry. In light of their results, probiotics may
Women with vulvovaginal atrophy, a common cause of vaginal dryness and
sexual pain, tended to have microbial compositions that were not dominatedby lactobacilli.
8/13/2019 Medical Tribune December 2013
16/38
16 December 2013 News
be a welcome alternative due to the draw-
backs in current therapy.
Women with vulvovaginal atrophy symp-
toms use lubricants during intercourse or
vaginal moisturizers as rst-line therapies.However, these may have detrimental ef-
fects on the vaginal lining, or may alter the
bacterial mix and increase susceptibility
to infections. In moderate-to-severe cases,
low-dose estrogen in the vagina is the cur-
rent therapeutic standard, but not all wom-
en can use vaginal estrogen, such as cancer
survivors, and some wish to avoid hormone
treatment.
The authors cautioned that using lactoba-cilli products that are not native to an in-
dividual womans vagina may be harmful.
Personalized probiotics, or other methods
to manage the bacterial mix, may be the so-
lution to treating vulvovaginal atrophy.
8/13/2019 Medical Tribune December 2013
17/38
17 December 2013 News
Seah Yee Mey
Scientists have recently identied and de-veloped a novel class of molecules thatappears to inhibit inuenza virus rep-
lication, a new study reports. [ACS ChemicalBiology2013; doi: 10.1021/cb400400j]
Researchers at Rutgers University, NewJersey, US, engineered part of the inuenzavirus replication enzyme and used it to screena library of 800 small molecule fragments forpotential sites of enzyme inhibition.
Fragment screening led them to the discov-ery of a previously unknown metal ion bind-ing location in the active site of the enzymethat could be exploited to inhibit viral replica-tion. Based on the screen, the researchers then
designed a new class of compounds to selec-tively block the inuenza virus enzymatic ac-tivity. When tested on cell cultures, the com-pounds demonstrated antiviral activity.
Were at a key proof of principle stageright now, said Eddy Arnold, professor ofchemistry and chemical biology at Rutgers,whose laboratory carried out the research incollaboration with Edmond LaVoie, professor
and chair of medicinal chemistry also at Rut-gers, and virologist Luis Martinez-Sobrido ofthe University of Rochester, New York. Itsnot trivial to go from this point to actuallydelivering a drug, but were optimistic thisclass of inhibitors has all the right characteris-tics, he said.
Just as bacteria develop antibiotic resis-tance, Arnold noted that some strains of inu-enza have also started to develop resistanceto oseltamivir phosphate, which is currentlythe only orally available anti-inuenza drug.
Therefore, Arnold and his collaborators aresearching for other drugs, especially ones thattarget other parts of the virus. They selected
this particular viral enzyme because inhibit-ing its activity interferes with the virus abilityto steal material from human cells and dis-guise itself.
The approach used by Arnold and his col-laborators has also helped in the developmentof anti-HIV drugs. Merck targeted metal ion-containing active sites in an HIV enzyme todevelop a successful anti-HIV drug. Its truly
remarkable what they did, and were trying topursue similar logic with inuenza, Arnoldsaid.
Antiviral drug discovery is an essentialalternative to vaccines, especially duringpandemics when timely vaccine productionis dicult. While this approach is not new,the technology to produce the high-resolu-tion images of the H1N1 inuenza enzymestructure used by the Rutgers researchersto screen for inhibitors is only recently avail-able.
Novel engineered molecule inhibits
influenza virus replication
Researchers in the US have designed a new class of compounds to selectivelyinhibit the inuenza virus enzymatic activity.
8/13/2019 Medical Tribune December 2013
18/38
18 December 2013 Research Reviews
Oral anticoagulants and antiplatelet drugs reduce risk of secondary
VTE
Venous thromboembolism (VTE) is the third
most common cardiovascular disorder. Al-
though potentially fatal, it can be treated and pre-
vented with anticoagulants, but there is a trade-o
with the risk of major bleeding events.
A recent systematic review and network meta-
analysis compared the ecacy and safety of the oral
anticoagulants dabigatran (150 mg twice daily), ri-
varoxaban (20 mg/day), apixaban (2.5 mg and 5 mg
twice daily), vitamin K antagonists (standard dose,
target international normalized ratio [INR] 2.03.0;low dose, target INR 1.53.0), ximelagatran (24 mg
twice daily), and an antiplatelet agent (acetylsalicylic acid 100 mg/day) for the secondary prevention of VTE. Lit-
erature searches of the Medline, Embase and Cochrane Register of Controlled Trials databases were performed
to identify randomized controlled trials in which patients received anticoagulants, antiplatelet drugs, or placebo
or observation. Twelve articles were identied and 11,999 patients were evaluated for ecacy and 12,167 for
safety.
All treatments reduced the risk of recurrent VTE. Compared with placebo or observation, standard-dose vita-
min K antagonists showed the greatest eect (odds ratio [OR] 0.07; 95% CI 0.03-0.15) followed by dabigatran (OR
0.09; 95% CI 0.04-0.21); acetylsalicylic acid had the smallest eect (OR 0.65; 95% CI 0.39-1.03). Among these three
agents, the risk of major bleeding was highest for the standard-dose vitamin K antagonists (OR 5.24; 95% CI 1.78-
18.25) versus placebo or observation. The corresponding odds ratios for dabigatran and acetylsalicylic acid were
2.79 (95% CI 0.79-11.69) and 1.29 (95% CI (0.4-4.08). Fatal VTE recurrence and major bleeding events were rare.
Castellucci LA et al. Ecacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism:
systematic review and network meta-analysis. BMJ 2013; 347: f5133
8/13/2019 Medical Tribune December 2013
19/38
19 December 2013 Research Reviews
Suicide ideation in relatives bereaved by suicide
Relatives bereaved by suicide are known to be at increased risk of suicide themselves irrespective of whetherthey are genetically related to the deceased family member or friend. A recent study has indicated that thismay be due to suicide ideation linked to symptoms of depression and complicated grief, which is a proposed
clinical entity related to bereavement that is distinct from depression, anxiety and post-traumatic stress disorder.
The study is unique in that it oers a long-term assessment of the course of bereavement.
The researchers analyzed data collected from a community-based sample of 153 rst degree relatives and
spouses of 74 individuals who commied suicide between September 1999 and January 2002 in the Netherlands.
The participants completed self-report questionnaires assessing symptoms of complicated grief, depression, and
suicidal ideation 2.5 months (baseline), 13 months, and 96-120 months (810 years) aer the index suicide.Suicide ideation, depression and complicated grief were strongly mutually associated. A total of 26 percent suf-
fered from suicide ideation at baseline, compared with 9 percent at 96-120 months. Long-term suicide ideation
was linked to a history of aempted suicide and was strongly associated with an increased risk of complicated
grief and depression. However, these risks decreased over time. Long-term depression was more common among
women and those with low levels of mastery. Parents who lost a child were at greater risk of complicated grief.
Family-based therapy, support from a general practitioner, and/or mental healthcare did not aect the long-term
course of bereavement. Mutual support provided by voluntary clergy- or peer-led groups was associated with
an increased risk of complicated grief, but the researchers caution that this may be due to selection bias.
de Groot M & Kollen BJ. Course of bereavement over 8-10 years in rst degree relatives and spouses of people who commied suicide: longitudinal community based
cohort study. BMJ 2013; 347:f5519.Neal B. Trials in kidney disease time to EVOLVE. Ibid:2541-2542 (editorial).
Treatments fail to reduce cough in acute bronchitis patients
Acute bronchitis is one of the most common complaints encountered by primary care physicians. The condition is
primarily caused by viral infection and is generally self-limiting, but most patients continue to be prescribed anti-biotic treatments, particularly if they report discoloration of sputum. Given the global increase in antibiotic resistance,
this over-prescription is of concern. Since cough is the primary symptom of acute bronchitis, oral anti-inammatory
therapy has been suggested as a more appropriate treatment. However, a recent study in Spain has shown that neither
oral anti-inammatory nor antibiotic treatment is more eective than placebo at reducing cough frequency.
The prospective, parallel group, single-blind study included 416 adults aged 18-70 who presented with symptoms
of respiratory infection of less than 1 week duration, predominately cough but also sputum discoloration and at least
one of the following: dyspnea, wheezing, chest discomfort or chest pain. The patients were randomized to ibuprofen
600 mg three times daily (n=136), amoxicillin-clavulanic acid 500 mg/125 mg three times daily (n=137) or placebo three
times daily (n=143) for 10 days. Symptom duration was assessed with a diary.
The median number of days with frequent cough was 9 (95% CI 810) among the ibuprofen recipients compared
with 11 (95% CI 10-12) among those who received the antibiotic. However, this dierence was not statistically signi-
cant. Moreover, the probability of cough resolution was not greater than that of placebo for both ibuprofen (hazard
ratio [HR] 1.03, 95% CI 0.781.35) and amoxicillin-clavulanic acid (HR 1.23, 95% CI 0.931.61).
Llor C et al. Ecacy of anti-inammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo
controlled trial. BMJ 2013;347:f5762.
8/13/2019 Medical Tribune December 2013
20/38
20 December 2013 Research Reviews
Coffee consumption positively correlated with all-cause mortality
Given the popularity of coee consumption world-
wide it is of no surprise that a recent study linkingcoee consumption with all-cause mortality has been
the subject of much comment, particularly since no such
association was observed with cardiovascular mortality.
In their study, the researchers evaluated observational
data from 43,727 individuals aged 20-87 years who were
enrolled in the prospective Aerobics Center Longitudi-
nal Study. All completed a medical history questionnaire
assessing their lifestyle habits and personal and family
history and underwent a baseline medical examination
between February 3, 1971 and December 30, 2002. Indi-
viduals with cardiovascular disease or cancer and those
who were underweight or had abnormal electrocardio-
graphic ndings were excluded, which le 43,727 in-
dividuals (33,900 men and 9,827 women with 699,632
person-years of follow-up) who met the inclusion crite-
ria and were observed for mortality from the baseline
examination to their date of death or December 31, 2003.
A total of 2,512 deaths occurred during the median 17-
year follow-up period. Multivariate analyses revealed anassociation between the consumption of >28 cups coee/
week and all-cause mortality in men only (hazard ratio
[HR] 1.21; 95% CI 1.04-1.40). However, stratication by
age indicated that coee intake >28 cups/week was asso-
ciated with all-cause mortality in both men and women
younger than 55 years (men: HR 1.56, 95% CI 1.301.87;
women: HR 2.13; 95% CI 1.26-3.59). Adjustments were made for age, baseline examination year, decaeinated
coee use, regular tea use, decaeinated or herbal tea use, physical inactivity, body mass index, smoking, alcohol
consumption, diabetes, hypertension, hypercholesterolemia, family history of cardiovascular disease, and physi-
cal tness.
The researchers stressed that further studies are needed to conrm their ndings, but they caution that young-
er individuals may be beer o avoiding excessive coee consumption (average >4 cups/day).
Liu J et al. Association of coee consumption with all-cause and cardiovascular disease mortality. Mayo Clin Proc. 2013; 88 (10): 1066-1074.
8/13/2019 Medical Tribune December 2013
21/38
21 December 2013 Research Reviews
Mixed microbial preparation offers no protection against AAD
Antibiotic-associated diarrhea (AAD) is a common
complication among inpatients aged 65 yearstreated with broad-spectrum antibiotics, which is con-
cerning since Clostridium dicileinduced AAD (CDD)
can be life-threatening. A variety of microbial prepara-
tions have been tested with the aim of ameliorating or
preventing AAD and CDD by restoring the gut micro-
bial ora, but their ecacy remains controversial. Re-
cently, a multicenter ecacy trial found no evidence of
any protective eect of a multistrain lactobacilli and bi-
dobacteria preparation against AAD or CDD.
The double-blind study evaluated 2,981 inpatients aged 65 years who were randomized to receive the micro-
bial preparation containing 61010 live bacteria (n=1,493) or placebo (n=1,488) once daily for 21 days. All patients
had been exposed to one or more antibiotics in the preceding 7 days or were about to begin antibiotic treatment.
Follow-up was for 8 weeks.
A modied intention-to-treat analysis of 2,941 participants revealed that AAD (including CDD) occurred in
10.61 percent of patients, and the incidence was similar between the treatment and placebo groups (relative risk
[RR] 1.04, 95% CI 0.84-1.28). Moreover, CDD was only observed in 0.99 percent, and again the incidence was
similar in both groups (RR 0.71, 95% CI 0.34-1.47). The microbial preparation did not appear to have any protec-
tive eect against diarrhea severity, frequency of abdominal symptoms, length of hospital stay or quality of life.
The researchers commented that a beer understanding of the pathophysiology of AAD is required.
Allen SJ et al. Lactobacilli and bidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium dicile diarrhoea in older inpatients
(PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; Aug 7 pii: S0140-6736(13)61218-0. doi: 10.1016/S0140-
6736(13)61218-0 [Epub ahead of print]
8/13/2019 Medical Tribune December 2013
22/38
22 December 2013 Conference Coverage
Adult brain continues to regenerate
neurons
7th Asian Society Against Dementia International Congress, October 9-12, Cebu, Philippines
Elvira Manzano
N
eurogenesis, the birth of neurons
or nerve cells in the hippocampus,
continues during adulthood, new
research suggests.A retrospective study of hippocampal cells
from deceased patients has shown that a sig-
nicant proportion (35 percent) of these neu-
ral cells are subject to exchange, resulting in
the addition of 700 new cells to the brain per
day per individual. This corresponds to an
average turnover rate of 1.75 percent of the
renewing cells per year during adulthood,
with no dierence in rates between genders(p=0.41). [Cell 2013;153:1219-1227]
Human studies like this are sparse but
encouraging, said Dr. Robert Hoerr, head of
geriatrics/CNS, Department of Clinical Re-
search, Dr. Willmar Schwabe GmbH & Co.
KG, in Karlsruhe, Germany, who was not in-
volved in the study. He said this adds weight
to the issue of adult neurogenesis in humans
and gives indirect indication of the extent ofneurogenesis which may have an impact on
brain function. Hoerr cited data from this
study, and other studies, during his plenary
lecture on hippocampal neurogenesis.
It has long been debated whether adult
neurogenesis decreases or increases through-
out life. A seminal study in 1998 provided the
only direct evidence so far of adult neurogen-
esis in humans, although it did not show the
extent of neurogenesis, or if there is any func-
tional signicance to it. [Nat Med1998;4:1313-1317]
In the current study, researchers measured
the amount of radioactive carbon 14 isotope
(14C) in genomic DNA from the hippocampal
cells of deceased patients (19-92 years of age),
to determine cell age. A mathematical model
was then developed to determine the rate of
cell turnover in both neural and non-neural
cells of the patients.A higher rate of cell turnover existed in
the non-neural cells than in the neural cells
(51 percent vs 35 percent), with an annual
turnover rate of 3.5 percent. This however
declined with age. By comparison, the neural
cells appeared to be less aected by aging.
Studies in mice and in humans linking neu-
rogenesis to Alzheimers disease (AD) yield-
ed conicting results [J Neurosci2007;27:6771-
6780; PNAS 2004;101:343-347]. In one study in
A new study suggests that the typical adult brain is regenerating an averageof 700 new cells per day.
8/13/2019 Medical Tribune December 2013
23/38
23 December 2013 Conference Coverage
humans, neurogenic abnormalities with AD
diered between phases and areas of neuro-
genesis, as well as stages of AD. [Neurobiol Dis
2012;47:155-162]
With progressing AD, choline-acetyl-transferase activity and hippocampal stem
cells decrease, proliferation of progenitor
cells increase, but migratory and post-miotic
cells largely remain unchanged, Hoerr said.
Several factors may inuence hippocampal
neurogenesis, he added. These include signal-
ing molecules, transcription factors, growth
factors, neurotransmiers and hormones.
Animal studies have shown that all current-
ly available anti-dementia drugs (donepezil,
galantamine, memantine), as well as antide-
pressants (eg, uoxetine), physical and men-
tal activities promote neurogenesis.
Ginkgo biloba extract (EGb 761) has also
been shown to stimulate neurogenesis in
mice. It reduced amyloid beta oligomers and
restored cAMP response element-bindingprotein (CREB) phosphorylation in the hippo-
campus, suggesting that EGb 761 not only has
benet in the treatment of patients with AD,
but may also have an eect in prevention or
disease modication. [FASEB J2007;21:2400-
2408]
Overall, the studies provide new informa-
tion on hippocampal neurogenesis and en-
courage additional research. Further studies
to determine if reduced neurogenesis is asso-
ciated with depression in humans would be of
interest, Hoerr concluded.
Playing video games boosts cognitiveperformance in seniors
Elvira Manzano
Video game training can improve cog-
nitive performance in healthy older
adults, new research has found.The study involving participants aged 60-
85 years showed that 12 hours of video game
training spread over 1 month increased their
multi-tasking capabilities, as well as cogni-
tive control (working memory and sustained
aention), beer than younger adults who
played it for the rst time. The improvements
were sustained 6 months aer the training had
ended. There were also increases in midline
frontal theta, or low frequency oscillations in
the prefrontal cortex, which is associated with
aention. [Nature2013; 501:97-101]
In a trial involving older adults, aged 60-85, 12 hours of video gamingspread over a month was associated with improvements in their multi-tasking abilities and cognitive control.
8/13/2019 Medical Tribune December 2013
24/38
24 December 2013 Conference Coverage
The study researchers warned the ndings
should not be taken to suggest that any activ-
ity or video game would improve cognition
in seniors. However, it does oer evidence
of generalized positive eects of video gametraining on cognitive control of older adults,
with enhancements comparable to those of
younger adults who are habitual video game
players, said Associate Professor Christopher
Chen from the Department of Pharmacology,
National University of Singapore.
Chen, who was not involved in the study,
said video game participation may be a po-
tential intervention strategy to increase cogni-
tive reserve in seniors.
The study by researchers at the University
of California in San Francisco, US, provides
optimism for use of an adaptive interference-
rich, video game approach as a therapeutic
tool for the diverse populations that suer
from cognitive control decits. It also stress-
es the importance of a targeted training ap-
proach.
The researchers used a custom-designed
three dimensional (3-D) race car video game
(NeuroRacer) and made the seniors drive at
full speed in between road signs for up to 12
hours on a laptop. The game gets harder as
they succeed and easier when they get frus-
trated. Driving up winding mountain roads
while picking out occasional road signs madethem work at both skills. This keeps them
challenged and engaged while having fun,
Chen said. Learning also improves when the
brains reward system is turned on, such as
when someone is having fun.
However, the most meaningful endpointsfor intervention in seniors, according to this
clinician-scientist, would be slowed rate of
age-related cognitive decline or reduced risk
of developing Alzheimers disease.
Controlled studies that use such endpoints
are however undoubtedly expensive and have
to be conducted over long periods of time.
Most likely, studies should also use multiple
intervention strategies, including exercise,
cognitive and social stimulation, Chen said.
In addition to that, a validated measure of
cognitive reserve (brain capacity built up dur-
ing early life), should be used when assessing
cognition in seniors. This does not preclude
the use of more challenging tests that are pa-
thology-specic and biomarkers in patients
with high cognitive reserve. Higher rate of
decline aer diagnosis may also be relevant
for clinical trials, he added.
Finally, clinicians need to have a beer
understanding of the neuroimaging cor-
relates, underlying genetic factors and the
role of cerebrovascular factors on cognitive
reserve. We need to develop and show ef-
cacy of interventions to improve cogni-
tive reserve and brain resilience, Chenconcluded.
8/13/2019 Medical Tribune December 2013
25/38
Along with a redesign that helps enhance ease of access to crucial clinical
information, MIMS.com can now be accessed through a FREE mobile
application,available on both the iTunes App Store and Google Play Store.
With MIMS available across multiple platforms and devices, you can now
easily and conveniently find the most up-to-date and relevant drug
information anytime, anywhere.
MIMS.com now comes with
a brand new look and mobile app!
Join over a million MIMSmembers who have incorporated MIMS
into their daily workfl ow. Connect with MIMS today.
MIMS mobile/tablet app facebook.com/mimscomwww.mims.com
8/13/2019 Medical Tribune December 2013
26/38
26 December 2013 In Practice
Management of codeine addiction in
primary care
Dr. Melvin Wu
Resident Physician
National Addictions Management Service (NAMS)
Institute of Mental Health, Singapore
GPs can be crucial to identifying and
helping codeine addicts get profes-sional help to kick their habit.
Codeine belongs to the opioid class of
substances that, in the short-term, can cause
drowsiness and endanger the patients life
while operating machinery or driving. At
higher dosages or when used in combination
with other substances such as benzodiaze-
pines and alcohol, codeine can cause respira-
tory depression and even death.Long-term use of codeine can lead to de-
pendence, characterized by tolerance and
withdrawal symptoms such as cravings,
runny nose, yawning, insomnia, weakness,
irritability, muscle spasms, body aches, diar-
rhea and vomiting. The paern of codeine use
becomes compulsive when the person has a
loss of control over its use. In other words, he
or she has become addicted to codeine. Therewill invariably be problems at home, work
and/or school in relation to this paern of use.
Reviewing the history of the persons clinic
visits is one way to identify if he or she may
have a problem with codeine addiction. For
example, they may have regular visits and
oen request for the same type of cough
mixture. They may be resistant to the idea
of changing the type of cough mixture. This
person may also ask for an extra bole of the
medication.
A simple way
to assess the pos-
sibility of addic-
tion would be to
ask the person if
he or she has had
problems with
addiction in thepast. A history of
addiction to any
substance will
increase the risk
that the person
may also be addicted to codeine.
GPs play an important role in helping the
person as they are oen the rst point of con-
tact. A non-confrontational way of approach-ing the subject would be to oer help for the
presenting problem, usually a chronic cough.
Start by saying, I notice that you have
been having this cough for quite a while now
and I am rather concerned. Next, oer inves-
tigations, eg, chest X-rays, and referral to a re-
spiratory physician.
If the person accepts this, it might point to
a genuine underlying disease concern. If thereare signs that this person is abusing codeine,
oer to change the type of cough mixture.
Choose a non-opioid based cough mixture
like diphenhydramine or ivy leaf extract. Be
rm in your stand that you will not continue
to prescribe codeine.
Providing psychoeducation to this person
on the dangers of long-term codeine use may
sometimes help them to open up and ask for
help.
8/13/2019 Medical Tribune December 2013
27/38
8/13/2019 Medical Tribune December 2013
28/38
28 December 2013 In Practice
gressive treatment. Inammatory processes
of the scalp include lichen planopilaris and
discoid lupus erythematosus.
Diagnosis
A thorough clinical history and careful
examination will help to establish a diag-
nosis. Doctors can use trichoscopy, a hand-
held dermatoscope to assess the hair and the
scalp. In FPHL, trichoscopy will show hair
diameter heterogeneity. Other relevant tools
for hair loss diagnosis include blood tests
with iron level measurements, thyroid func-
tion tests, autoimmune markers and hor-
monal assessment. In some dicult cases,
a skin biopsy of the scalp may be needed.
Conditions like scarring alopecia oen man-
date scalp biopsies.
Treatment
Optimal results for hair loss management
stem from early treatment as it is always easi-er to arrest hair loss at an earlier stage than to
grow hair at a later stage. GPs can help recog-
nize the beginning stages of hair loss, counsel
patients on their options and refer to derma-
tologists for treatment.
Treatment for hair loss requires a tailored
approach. Any underlying causes should be
corrected, including iron deciency, thyroid
abnormalities and other metabolic abnormal-ities. This should be followed with regular
follow-ups with photographic documenta-
tion to assess for treatment results. Realistic
expectations need to be set with the patient.
Treatments tend to work beer when initiated
early or used in combinations.The goal of treating FPHL is to stop hair
loss and stimulate hair growth. The treat-
ment for FPHL can be divided into andro-
gen-independent and androgen-dependent.
Androgen-independent therapies include
topical minoxidil. Minoxidil is currently the
standard of care for FPHL and its ecacy has
been proven in randomized, double-blinded
trials. Its mechanism of action remains specu-
lative and is thought to involve vasodilatory
and anti-androgenic eects. It is usually well
tolerated. Some adverse eects to counsel
patients about include: facial hair if solution
drips beyond hair line, itch and dandru.
Androgen-dependent therapies for FPHL
usually consist of androgen receptor antago-
nists like spironolactone and cyproterone ac-
etate. Spironolactone is a diuretic that reduces
the total testosterone and blocks the androgen
receptor. It has been used to treat FPHL o-
label. Spironolactone must be used carefully
in females of child bearing age as it is contra-
indicated in pregnancy. Patients started on
spironolactone must be counseled that they
will need regular monitoring of their potas-
sium levels, whilst some may expect transientmenorrhagia. Cyproterone acetate has shown
ecacy in treating FPHL in women of normal
or raised androgen levels.
The treatment of alopecia areata depends
on the area of involvement. For small areas of
involvement, intralesional corticosteroids can
be used. Rapidly progressive diuse alopecia
areata can be dicult to dierentiate from
other causes of diuse hair loss and such pa-tients are best referred for specialist opinion.
GPs can help recognize the
beginning stages of hair loss,
counsel patients on their options
and refer to dermatologists
for treatment
8/13/2019 Medical Tribune December 2013
29/38
29 December 2013 In Practice
A scalp biopsy may sometimes be needed to
ascertain the diagnosis. Rarely, systemic corti-
costeroids may be needed for short periods to
arrest rapidly progressing hair fall. For alope-
cia areata involving large areas of scalp, topi-cal immunotherapy is also a treatment option.
Realistic results for hair regrowth oen
take many months to achieve. Providing
the necessary psychological support for pa-
tients is very important. While waiting for
hair to regrow, patients can seek to camou-
age hair loss using various methods, in-
cluding hair pieces, wigs or scalp camou-
aging agents.
Hair transplant can be considered in patients
who have failed medical treatment or whose
advanced condition is unlikely to benet from
medical treatment. Such patients should have
stable hair loss, a good hair donor area, good
health and reasonable expectations.
A specialist opinion should be sought
when the diagnosis is uncertain or when there
is a doubt regarding treatment options. In
treatment of hair loss, a good patient-doctor
relationship is paramount. A referral may be
made when a doctor is experiencing time con-straints or limited resources, and a patients
desires a more in-depth discussion regarding
their hair loss and options.
Conclusion
Hair loss in women is a signicant prob-
lem. It is important to educate and coun-
sel patients about the treatment options for
hair loss. This should be done with com-
passion and patience to achieve the best
treatment outcome for the patient. While
numerous unproven and non-medical com-
mercial options for hair loss beckon, would-be
patients must realize that only doctors are
able to provide quality, scientically-based
treatments for their hair loss.
Online Resources:
American Hair Loss Associationhp://www.americanhairloss.org/
American Academy of Dermatologyhp://www.aad.org/media-resources/stats-and-facts/conditions/hair-loss
National Alopecia Areata Foundationhp://www.naaf.org
8/13/2019 Medical Tribune December 2013
30/38
30 December 2013 Calendar
DECEMBER
International Diabetes Federation (IDF) World
Diabetes Congress
2/12/2013 to 6/12/2013
Location: Melbourne, AustraliaInfo: IDFTel: (32) 2 543 1631Fax: (32) 2 403 0830E-Mail: [email protected]: www.idf.org/worlddiabetescongress
American Society of Hematology (ASH) Annual
Meeting
7/12/2013 to 10/12/2013Location: New Orleans, Louisiana, USInfo: ASHTel: (1) 202 776 0544Fax: (1) 202 776 0545Website: www.hematology.org
San Antonio Breast Cancer Symposium (SABCS)
2013
10/12/2013 to 14/12/2013Location: San Antonio, Texas, USInfo: Rich Markow, Director, SymposiaTel: (1) 210 450 1550Fax: (1) 210 450 1560E-Mail: [email protected]: www.sabcs.org
Health Systems in Asia: Equity, Governance and
Social Impact
13/12/2013 to 16/12/2013Location: SingaporeInfo: L. Copeland, ElsevierEmail: [email protected]: www.healthsystemsasia.com
International Conference on Obstetrics and
Gynaecology (ICOG) 2013
24/12/2013 to 25/12/2013Location: Bangkok, Thailand
Info: WASETTel: (1) 971 559 099 620Website: www.waset.org/conference/2013/12/bangkok/icog
JANUARY
17th Bangkok International Symposium on HIV
Medicine 2014
15/1/2014 to 17/1/2014
Location: Bangkok, ThailandInfo: Mrs. Kesdao Nanthapisal, HIV Netherlands AustraliaThailand Research Collaboration (HIV-NAT)Tel: (662) 652 3040, Ext. 123Fax: (662) 252 7574Email: [email protected]: www.hivnat.org/bangkoksymposium
16th Congress of the European Society for
Sexual Medicine
29/1/2014 to 1/2/2014Location: Istanbul, TurkeyInfo: ESSM Secretariat
Tel: (39) 25 6601 625Fax: (39) 27 0048 577Email: [email protected]: www.essm-congress.org/congress
2nd International Conference on Nutrition and
Growth30/1/2014 to 1/2/2014Location: Barcelona, SpainInfo: Kenes InternationalTel: (41) 22 908 0488Fax: (41) 22 906 9140Email: [email protected]: ng.kenes.com
UPCOMING
10th Asian Pacific Congress of Hypertension
(APCH)
12/2/2014 to 15/2/2014Location: Cebu, PhilippinesInfo: APCH SecretariatTel: (66) 2 748 7881
Fax: (66) 2 748 7880E-Mail: [email protected]: www.apch2014.org
8/13/2019 Medical Tribune December 2013
31/38
31 December 2013 Calendar
3rd Global Congress for Consensus in Pediatrics
& Child Health (CIP)
13/2/2014 to 16/2/2014Location: Bangkok, ThailandInfo: Paragon GroupTel: (41) 22 533 0948
Fax: (41) 22 580 2953E-Mail: [email protected]: www.cipediatrics.org
19th World Congress on Controversies in
Obstetrics, Gynecology & Infertility (COGI)
20/2/2014 to 23/2/2014Location: Macau, ChinaInfo: COGI SecretariatTel: (972) 73 706 6950Fax: (972) 3 725 6266E-Mail: [email protected]: www.congressmed.com/cogimacau
5th Congress of Asia Pacific Pediatric Cardiac
Society (APPCS)
6/3/2014 to 9/3/2014Location: New Delhi, IndiaInfo: APPCS SecretariatTel: (91) 11 2658 8116Fax: (91) 11 2658 8663E-Mail: [email protected]: www.appcs2014.org
Asian Pacific Association for the Study of theLiver (APASL) 2014
12/3/2014 to 15/3/2014Location: Brisbane, AustraliaInfo: Gastroenterological Society of AustraliaTel: (61) 3 9001 0279Fax: (61) 3 9802 8533E-Mail: [email protected]: www.apasl2014.com
WCO-IOF-ESCEO World Congress of Osteoporosis
2/4/2014 to 5/4/2014Location: Seville, Spain
Info: Yolande Piette CommunicationTel: (32) 4 254 12 25Fax: (32) 4 125 12 90Email: [email protected]: www.wco-iof-esceo.org
20th ASEAN Federation of Cardiology Congress
2014
12/6/2014 to 15/6/2014Location: Kuala Lumpur, MalaysiaInfo: AFCC SecretariatTel: (60) 3 7955 6608
Fax: (60) 3 7956 6608Website: www.nham-conference.com/?event=3&cmd=home
8/13/2019 Medical Tribune December 2013
32/38
32 December 2013 After Hours
Searching out Italian food and
wine heavenI N P I E D M O N T
Situated in Italys North-west, the Piedmont is rich in culture and history. Surrounded on
three sides by the Alps it also features the highest mountain peaks and largest glaciers in the
country. The Piedmont is also well known for its culinary delights and Alexandra Kirsten
reports on her recent trip for a lile wine tasting and true hunting.
It was the Alps that gave the Piedmont
(in Italian, Piemonte) its name: foot of
the mountain. While the mountains
attract skiers and other sportspeople, the
most interesting parts for food lovers are
the wavering hills and valleys of Langhe
and Monferrato. Dotted with small townsand pittoresque castles, the hills are home
to uncountable vineyards. No wonder the
special grapes in this region produce some
of the best wines from Italy such as Barolo,
Barbaresco, Barbera, Dolcetto and Moscato
DAsti.
Food and wine
Whilst in Piedmont, it is well worth go-ing on a tour of the vineyards. Many of
them especially the smaller ones offer
free wine tasting and a look into the wine
cellar. If you find a chatty wine dresser, you
will also get a small introduction to wine
growing, a history of the Piedmont, Italian
politics or, depending on your Italian, any-
thing else.
If you feel peckish after a long day of
tasting, the Piedmont offers unique food.
Its cuisine is mostly known for the immense
variety of antipasti (starters): in any other
8/13/2019 Medical Tribune December 2013
33/38
33 December 2013 After Hours
area, these filling dishes and the ubiquitous
grissini, long thin breadsticks, would
easily qualify as main courses. Famous ap-
petizers are bagna cuda, a butter saucemade with garlic and anchovies and served
with raw vegetables, insalata di carne cru-
da, minced raw beef with a marinade of ol-
ive oil and garlic or frittata, a baked veg-
etable omelet. In the unlikely case that you
are still hungry after these starters indulge
yourself with meat cooked in Piedmontese
red wine or, more on the vegetarian side,
with risotto and tajarin, a special kind ofpasta. If you are [very] adventurous try the
Finanziera, a dish made of cockscombs
and mixed organs or fried pigs feet called
Batsoa, literally translated as silk stock-
ings. Not everybodys delight though.
Gold of the earth
The Piedmontese cuisine would be less
famous without its favorite ingredient: thetruffle. Every year in autumn the small
town of Alba becomes the host of the Inter-
national Truffle Fair. Two weeks are dedi-
cated to the tuber magnum pico, includ-
ing gastronomic events and cultural and
folkloristic presentations.
Once known as witches food, truffles are
now beloved by gourmet chefs the world
over. The rare fungus grows only from Sep-tember to January, needs special soil, and
cannot be cultivated. This, and their ex-
traordinary taste, explain why truffles are
so expensive. In addition, truffles grow
underground. They can only be found by
very delicate noses, so the trifulau (truf-
fle gatherer) needs help from a canine com-
panion.
During the truffle season going on a
truffle hunt with a Trifulau and his dog is
an interesting experience. You will learn all
about black and white truffles and see the
dog in action. But be warned, you are not
allowed to keep the truffles you find.
The capital of baroque
Its not all about food and wine in the
Piedmont. Turin, the regions beautiful
capital is known as the little Paris. Wideboulevards, palaces, churches and castles
built during the kingdom of the Savoia give
the city an aristocratic look. Turin is an im-
portant hub of technology and culture: it
is not only home to the FIAT automobile
company but also to the famous Shroud
of Turin. But being the capital of the food-
loving Piedmont theres no wonder that the
Torinesi are also master chocolatiers. Gi-
anduja, chocolate made from hazelnuts
8/13/2019 Medical Tribune December 2013
34/38
34 December 2013 After Hours
growing in the area, is known and beloved
world-wide.
If you finally need a break from all the
food and culture, go and see the Pink Bun-
ny of Coletto Fava. On a hill in the northernpart of the country, a 60 meter long toy bun-
ny made of straw-stuffed fabric has been
laid out by a Viennese art group. Hikers and
tourists are encouraged to climb the over-
sized stuffed animal and even to lie down
for a nap or picnic on the wooly carcass.
You can be sure to find no truffles or grapes
there.
Photos courtesy of Alexandra Kirsten.
8/13/2019 Medical Tribune December 2013
35/38
Essential Clinical
Practice Tool
On-The-Go
The FREEMIMS app delivers critical prescribing information,medical news and CME articles as well as clinical calculators
essential to physicians daily practice needs.
With MIMS available across multiple platforms and devices,
you can now easily and conveniently find the most up-to-date
and relevant drug information you need anytime, anywhere.
MIMS mobile/tablet app facebook.com/mimscomwww.mims.com
Join over a million MIMSmembers who have incorporated MIMS
into their daily workfl ow. Connect with MIMS today.
8/13/2019 Medical Tribune December 2013
36/38
36 December 2013 Humor
Lets go back to your childhood!
You seem to be in good health.An early sign that eventually
youre going to be sick!
I can never tell if its a veinor an artery!
Youre back on solidsMr. Slickmore!
Youre right Doctor. Theres no
shortage of beds in this hospital,just too many patients!
I eat so much non-fattening food,how come Im still fat?
Its mid-life alright, but you havent reached the crisis yet!
8/13/2019 Medical Tribune December 2013
37/38
In this Series, find out what these experts have to say about the importance of earlydiagnosis of rheumatoid arthritis, their perspectives on overcoming complianceissues and updates on novel treatments.
Novel Treatmentsin the Management of
Rheumatoid Arthritis
SCAN TO WATCH VIDEO
Brought to you by MIMS
MIMS Video Series features
interviews with leading experts
Professor Josef Smolen
talks about early intervention
and treatment targets inrheumatoid arthritis
Professor Robert Moots
discusses how treatment has
evolved for patients withrheumatoid arthritis and theimportance of compliance
Dr Chi-Chiu Mok
shares his perspectives on
overcoming the challengesand issues in the managementof rheumatoid arthritis in Asia
For A 5-minute UpdateGo towww.mims.asia/video_series
8/13/2019 Medical Tribune December 2013
38/38
Publisher : Ben Yeo
Managing Editor : Greg Town
Senior Editor : Christina Lau
Contributing Editors : Jacky Suen, Jenny Ng(Hong Kong), Saras Ramiya,
Pank Jit Sin, Malvinderjit KaurDhillon (Malaysia), Dr Maria Trina
Florcruz (Philippines), RadhaChitale,Elvira Manzano, Rajesh
Kumar, Grace Ling (Singapore)
Publication Manager : Marisa Lam
Designers : Razli Rahman, Charity Chan,Lisa Low, Joseph Nacpil,
Agnes Chieng, Sam Shum,Cindy Ang, Sharen Lee
Production : Edwin Yu, Ho Wai Hung,Jasmine Chay
Circulation Executive : Christine Chok
Accounting Manager : Minty Kwan
Advertising Co-ordinator : Rachael Tan
Published by : MIMS (Hong Kong) Limited27th Floor, OTB Building,160 Gloucester Road,
Wanchai, Hong Kong
Tel: (852) 2559 5888Fax: (852) 2559 6910Email: [email protected]
Advertising Enquiries:
China : Yang XuanTel: (8621) 6157 3888
Email: [email protected]
Hong Kong : Kristina Lo-Kurtz, Miranda Wong,Marisa Lam, Jacqueline CheungTel: (852) 2559 5888
Email: [email protected]
India : Monica Bhatia
Tel: (9180) 2349 4644Email: [email protected]
Korea : Choe Eun YoungTel: (822) 3019 9350
Email: [email protected]
Malaysia : Sheena Subash, Lee Pek Lian,
Sumitra Pakry, Grace YeohTel: (603) 7954 2910
Email: [email protected]
Philippines : Marian Chua, Kims Pagsuyuin,
Rowena Belgica, Philip KatipunanTel: (632) 886 0333
Email: [email protected]
Singapore : Jason Bernstein, Carrie Ong,
Josephine Cheong, Melanie NyamTel: (65) 6290 7400
Email: [email protected]
Thailand : Wipa Sriwijitchok
Tel: (662) 741 5354Email: [email protected]
Vietnam : Nguyen Thi Lan Huong, Nguyen Thi My Dung
Tel: (848) 3829 7923Email: [email protected]
Europe/USA : Kristina Lo-KurtzTel: (852) 2116 4352
Email: [email protected]
Medical Tribune is published 12 times a year (23 times in Malaysia) by
MIMS Pte Ltd. Medical Tribune is on controlled circulation publication to
medical practitioners in Asia. It is also available on subscription to members
of allied professions. The price per annum is US$48 (surface mail) andUS$60 (overseas airmail); back issues at US$5 per copy. Editorial matter
published herein has been prepared by professional edi torial staff. Views
expressed are not necessarily those of MIMS Pte Ltd. Although great
effort has been made in compiling and checking the information given
in this publication to ensure that it is accurate, the authors, the publisher
and their servants or agents shall not be responsible or in any way liable
for the continued currency of the information or for any errors, omissions
or inaccuracies in this publication whether arising from negligence or
otherwise howsoever, or for any consequences arising therefrom. The
inclusion or exclusion of any product does not mean that the publisher
advocates or rejects its use either generally or in any particular field or
fields. The information contained within should not be relied upon solely
for final treatment decisions.
2013 MIMS Pte Ltd. All rights reserved. No part of this publication
may be reproduced in any language, stored in or introduced into aretrieval system, or transmitted, in any form or by any means (electronic,
mechanical, photocopying, recording or otherwise), without the written
consent of the copyright owner. Permission to reprint must be obtained
from the publisher. Advertisements are subject to editorial acceptance
and have no influence on editorial content or presentation. MIMS Pte
Ltd does not guarantee, directly or indirectly, the quality or efficacy of
any product or service described in the advertisements or other material
which is commercial in nature.
Philippine edition: Entered as second class mail at the Makati Central
Post Office under Permit No. PS-326-01 NCR, dated 9 Feb 2001. Printed
by KHL Printing Co Pte Ltd, 57 Loyang Drive, Singapore 508968.